The raised guidance and strong Life Sciences performance are the key positives. Monitor the Xodus Medical acquisition closing and its impact on the full-year outlook, as well as the restructuring plan's execution and savings realization timeline.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 5 $254.12entry
- T+1 · 11d ago −0.72%α −1.03% · $252.30
- T+5 · 5d ago −0.27%α −3.56% · $253.44
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
STERIS reported fiscal Q2 2027 adjusted EPS of $2.94, beating the $2.68 consensus by 9.7%, and revenue of $1.6B (+9% YoY) vs. $1.56B consensus. The company raised its full-year adjusted EPS guidance to $11.35-$11.55 from $11.10-$11.30, citing solid underlying demand and ~$0.18 benefit from tariff refunds. Life Sciences revenue grew 18% and guidance for that segment was raised, while Healthcare and AST met expectations.
Key Financial Metrics
Key Facts
- Adjusted EPS $2.94 vs. consensus $2.68 (beat by 9.7%)
- Revenue $1.6B vs. consensus $1.56B (beat by 2.6%)
- Revenue +9% YoY; constant currency organic revenue +8%
- FY2027 adjusted EPS guidance raised to $11.35-$11.55 from $11.10-$11.30
- Life Sciences segment revenue +18% YoY; segment guidance raised to 9-10% from 6-7%
- Tariff refunds contributed ~$0.18 to the guidance increase
- New restructuring plan with ~$45M total charges, ~$9M annualized savings
- Free cash flow for H1 FY2027 was $492.5M vs. $527.7M prior year
Financial Impact
Adjusted EPS beat consensus by $0.26 (9.7%); revenue beat by ~$40M (2.6%); FY guidance raised by $0.25 at midpoint
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Healthcare | $1.1B | +9.0% |
| Applied Sterilization Technologies | $295.6M | +5.0% |
| Life Sciences | $170.6M | +18.0% |
Risk Factors
- Free cash flow declined 6.7% in H1 due to working capital timing
- Restructuring charges of ~$45M may weigh on near-term reported results
- Tariff refund benefit is non-recurring and may not repeat
- Healthcare segment operating income growth lagged revenue growth due to inflation and investments
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3395890 |
Track record
21 reports on STE
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $264.32 Now $264.32 +0.00% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $264.32 Now $264.32 +0.00% settles Nov 20
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $264.32 Now $264.32 +0.00% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $253.44 Now $264.32 +4.29% settles Nov 19
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $256.27 Now $264.32 +3.14% settles Nov 18
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $254.12 to $253.44 Now $264.32 +4.01% ▼ −0.27% −3.56% vs SPY
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Viewing Entry $254.12 to $253.44 Now $264.32 +4.01% ▼ −0.27% −3.56% vs SPY
- Oct 28, 202619d ago Press Release Neutral 2/10 Entry $232.14 to $254.12 Now $264.32 +13.86% ▲ +9.47% +14.19% vs SPY
- Oct 20, 202627d ago Press Release Neutral 1/10 Entry $221.48 to $228.49 Now $264.32 +19.34% ▲ +3.17% +3.61% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers